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Abstract:  Aptamers are single-stranded oligonucleotides of DNA or RNA that bind to 
target molecules with high affinity and specificity. Typically, aptamers are generated by an 
iterative  selection  process,  called  systematic  evolution  of  ligands  by  exponential 
enrichment (SELEX). Recent advancements in SELEX technology have extended aptamer 
selection from comparatively simple mixtures of purified proteins to whole living cells, 
and now cell-based SELEX (or cell-SELEX) can isolate aptamers that bind to specific 
target cells. Combined with nanotechnology, microchips, microfluidic devices, RNAi and 
other  advanced  technologies,  cell-SELEX  represents  an  integrated  platform  providing 
ultrasensitive and highly specific tools for clinical medicine. In this review, we describe the 
recent  progress  made  in  the  application  of  cell-SELEX  for  diagnosis,  therapy  and 
biomarker discovery. 
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1. Introduction 
Aptamers  are  single-stranded  RNA  or  DNA  sequences  that  bind  to  target  molecules  with  high 
affinity and specificity. Aptamer molecules exist in nature in the form of genetic regulators called 
riboswitches [1], but artificial aptamers can be obtained by an in vitro selection process known as 
systematic  evolution  of  ligands  by  exponential  enrichment  (SELEX),  first  described  by  two 
independent laboratories in 1990 [2,3]. The SELEX process starts with a random pool of 10
13–10
16 
ssDNA or ssRNA molecules subjected to iterative rounds that specifically enrich sequences having 
high  binding  affinity  to  the  target  molecules.  In  vitro  SELEX  has  been  widely  used  for  the 
identification of a variety of targets, ranging from small molecules (metal ions, organic dyes, amino 
acids, or short peptides) to large proteins or complex targets (whole cells, viruses, virus-infected cells, 
or bacteria). The ability of aptamers to selectively bind to different targets is based on their distinct 
three-dimensional structure, allowing them to form stable and specific complexes with different targets 
of  complementary  shape  [4,5].  Thus,  in  view  of  target  inhibition,  aptamers  are  different  from 
ribozymes  and  antisense  oligonucleotides,  which  are  used  to  prevent  the  translation  of  genetic 
information from mRNAs to proteins [6]. The binding affinity of aptamers to their targets is very high, 
with typical dissociation constants in the picomolar to nanomolar range, depending on the nature of the 
targets. Also, aptamers recognize their targets with extremely high specificity. For example, aptamers 
can discriminate among homologous proteins that contain only a few amino acid changes [7–9].  
The molecular recognition properties of aptamers, such as high affinity and specificity, are similar 
to antibodies, but the unique properties of aptamers set them apart from antibodies. Aptamers are 
produced by chemical synthesis rather than tedious biological expression. This allows researchers to 
quickly  and  reproducibly  synthesize  any  DNA  or  RNA  sequence  with  little  or  no  batch-to-batch 
variation. As synthetic molecules, aptamers readily support site-specific modifications toward a specific 
purpose. For research, aptamers can be easily labeled with florescent dyes, biotin or radionuclides. For 
clinical  purposes,  aptamers  can  be  conjugated  to  nanoparticles  [10],  drug  molecules  [11],  
enzymes [12], viruses [13] or small interfering RNAs (siRNAs) [14]. Unlike antibodies, aptamers are 
very  stable  across  a  wide  range  of  temperature  or  storage  conditions.  Even  thermally-denatured 
aptamers can return to their original conformation without losing binding affinity by one cycle of 
heating  and  cooling,  whereas  antibodies  are  temperature  sensitive  and  denaturation  is  usually 
irreversible. In addition, chemical modifications, such as 2'-fluoro and 2'-O-methyl substitutions, can 
enhance their biochemical stability against nuclease degradation [4,15]. Furthermore, their small size 
allows for rapid penetration into tissues and organs, with low toxicity and low immunogenicity, which 
may facilitate long-term therapeutic efficacy and safety. These unique biochemical properties make 
aptamers highly suitable for the detection, diagnosis and treatment of disease.  Int. J. Mol. Sci. 2012, 13                       
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2. Cell-SELEX 
Typically, aptamers are selected by performing in vitro SELEX against a purified protein. Using 
purified  proteins  as  targets  has  the  advantage  of  easily  achieving  specific  enrichment  during  the 
selection process if the target protein assumes a stable conformation. Based on this method, high-affinity 
aptamers against purified MUC1 peptides [16], the purified extracellular domain of prostate-specific 
membrane  antigen  (PSMA)  [17],  cell  adhesion  molecule  P-selectin  [18]  and  protein  tyrosine 
phosphatase 1B (PTP1B) [19] have been isolated. When target proteins are present in a modified state, 
however, or if the potential binding domain is masked in a physiological context, the isolated aptamers 
might not recognize the natural structure of some proteins. Liu et al. selected RNA aptamers against 
the histidine-tagged EGFRvIII ectodomain produced by the Escherichia coli expression system [20]. 
Although generated aptamers exhibited high affinity and specificity for in vitro purified protein, it did 
not  bind  the  full-length  EGFRvIII  protein  expressed  on  the  surface  of  eukaryotic  cells,  probably 
because a post-translational modification altered the structure of EGFRvIII.  
To avoid the disadvantage of selected aptamers against a non-native protein conformation, a strategy 
using whole living cells as targets for aptamer selection, termed cell-SELEX, has been developed. 
Unlike  protein-based  SELEX,  cell-SELEX  does  not  require  any  prior  knowledge  of  the  protein 
conformation. Also, it is unnecessary to purify target proteins by processes that may disrupt the native 
conformation. All cell-surface molecules will remain in their native environment, retain native folding 
structure and contain possible post-translational modifications throughout the selection process. Thus, 
aptamers selected using whole live cells will be able to bind to the natural folded conformation of the 
target on cells. This shows great potential in biomedical research and in the development of cell-specific 
diagnosis and therapeutics. 
To generate aptamers against whole living cells, target and negative cells must first be considered. 
In general, molecular differences between any two closely-related cell populations, such as tumor cells 
and  normal  cells,  determine  the  number  of  SELEX  rounds  required  and  the  overall  success.  To 
enhance the specificity of the aptamers, negative cells are used in a counter-selection step to avoid the 
enrichment of aptamers for abundant nonspecific proteins. To monitor enrichment by flow cytometry, 
the sense strand of the primer is labeled with a fluorophore, whereas sense strands are separated from 
antisense by conjugating biotin to the reversible primer for streptavidin-biotin interaction [21]. 
A typical selection cycle for a suspension of cells is shown in Figure 1. Briefly, concentration and 
viability  need  to  be  determined  before  selection.  After  serum  is  removed  from  culture  media  by 
thorough washing, the target cells are incubated with ssDNA on a rotary shaker for a specified time 
and at a specified temperature, depending on the purpose of selection. Second, unbound aptamers are 
washed away and bound sequences are eluted by heat denaturation for 15 min at 95 °C. Third, the 
eluted sequences are amplified by PCR or used for counter-selection. If counter-selection is desired, 
the negative cells are incubated with the eluate, and the unbound ssDNAs are separated by centrifugation 
and amplified by PCR. Fourth, the amplified dsDNA products are bound to streptavidin beads. The 
antisense strand with biotin is retained on the beads, and the sense strand is eluted with NaOH, which 
does not dissociate the biotin-streptavidin bond. The eluted ssDNAs are the enriched pool from the 
first round of selection and are then used to construct a library for the next round of selection. In 
general, the concentration of cells, DNA, fetal bovine serum, ionic strength, and incubation times and Int. J. Mol. Sci. 2012, 13                       
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temperatures are varied such that each round becomes more stringent, thus favoring the selection of 
high affinity aptamers.  
Figure 1. Schematic representation of DNA aptamer selection using the cell-SELEX strategy. 
 
Since cell-SELEX has the advantage of direct selection of aptamers without previous knowledge  
of the target molecule, this strategy has been widely adopted to generate aptamers that are capable  
of  recognizing  different  cell  populations,  including  red  blood  cells  (RBCs)  [22],  lymphocytic  
leukemia [23], myeloid leukemia[24], liver cancer [25], small cell lung cancer [26,27], non-small cell 
lung  cancer  [28]  and  ovarian  cancer  cells  [29].  Recently,  we  extended  aptamer  selection  by  
cell-SELEX  to  include  clinical  samples.  By  using  a  human  precursor  T-cell  acute  lymphoblastic 
leukemia (T-ALL) cell line, CCRF-CEM, as the target and the human Burkitt’s lymphoma cell line 
Ramos  as  negative  cells,  we  successfully  obtained  the  aptamer  sgc3  that  specifically  recognized 
cultured leukemia T cells [23]. Furthermore, we applied sgc3 to clinical samples and found that sgc3 
exhibited stronger binding affinity to T-lineage acute lymphoblastic leukemia (ALL) samples than to 
acute myeloid leukemia (AML) and normal bone marrow samples (Figure 2).  
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Figure  2.  Binding  assay  of  sgc3  in  normal  bone  marrow,  AML  and  T-ALL  by  
flow cytometry. 
     
Normal bone marrow  AML  T-ALL 
3. Cell-Specific Aptamers for Biomarker Discovery 
Biomarkers  indicate  a  change  in  the  expression  or  state  of  proteins  or  genes  under  changing 
physiological conditions or during pathogenesis, thus providing an important tool for clinical diagnosis, 
monitoring and treatment. The discovery of novel biomarkers not only leads to a greater understanding 
of  disease  processes,  but  also  is  of  great  clinical  value  for  early  detection  and  prompt  treatment. 
Although proteomic methods, such as two-dimensional gel electrophoresis (2D-GE) and differential 
imaging gel electrophoresis (DIGE), followed by mass spectrometric identification of proteins, are 
employed for new biomarker discovery, the elucidation of membrane proteins that are differentially 
expressed in disease is still a great challenge [30,31].  
Aptamers generated by cell-SELEX facilitate biomarker discovery for membrane protein. As noted 
above, aptamers can recognize different types of cells, based on molecular difference of unknown 
membrane proteins on  disease cells compared  with normal cells. Thus, it is conceivable that new 
biomarkers could be discovered as long as the aptamer’s target protein can be identified. Following 
this  idea,  aptamer-based  target  membrane  protein  identification  had  been  developed  by  affinity 
purification, followed by sequencing using mass spectrometry. For example, Daniels et al. used a 
glioblastoma-derived cell line, U251, as the target for cell-SELEX. The aptamer GBI-10 was identified 
and  shown  to  specifically  target  U251  cells  [32].  Furthermore,  by  using  affinity  purification  and  
LC-MS/MS analysis, the extracellular matrix protein tenascin-C was determined to be the binding 
partner of GBI-10. Tenascin-C is a large glycoprotein that is highly expressed in the microenvironment 
of most solid tumors, which is involved in uncontrolled proliferation, angiogenesis and metastasis of 
tumor cells [33].  
Using  cell-SELEX,  we  developed  DNA  aptamers  that  specifically  bind  to  CCRF-CEM  cells,  a 
human precursor T-cell acute lymphoblastic leukemia (T-ALL) cell line. In cell-SELEX, a B cell line 
from  human  Burkitt’s  lymphoma,  Ramos,  was  used  as  the  negative  control  for  counter-selection.  
After 20 rounds of selection, aptamer sgc8 was isolated and showed high specificity and affinity for 
CCRF-CEM leukemia cells, while showing no specific binding to lymphoma cells or normal bone 
marrow  cells  [34].  To  identify  target  protein  of  sgc8  for  biomarker  discovery,  aptamer-mediated 
affinity purification of protein targets was performed. Membrane lysate was incubated with sgc8, labeled 
with a biotin tag at the 5'-end. The binding complex was then separated using streptavidin-coated 
magnetic beads. After the captured proteins were eluted by heating and separated by SDS-PAGE, Int. J. Mol. Sci. 2012, 13                       
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characteristic protein bands on the gel were digested and analyzed using LC-MS/MS QSTAR. Finally, 
PTK7, a transmembrane receptor tyrosine kinase-like molecule, was successfully identified as a potential 
biomarker for T-cell acute lymphoblastic leukemia [35].  
The same strategy was also adopted for purification and identification of immunoglobulin   heavy 
chain (IGHM), a molecular target of aptamer TD05 developed for Ramos cells [36]. To increase the 
stability  of  the  aptamer-protein  complex,  TD05  was  modified  with  photoactive  5-dUI  to  promote 
covalent cross-linking to the target protein. This modification of TD05 also facilitated the purification 
and enrichment of the target protein from cell lysate. The IGHM is one of the major components of  
B-cell  receptor  complex  expressed  in  mature  Burkitt’s  lymphoma  cells,  and  IGHM  expression  on 
premature  B-lymphocytes  is  closely  related  to  the  development  of  Burkitt’s  lymphoma.  Thus,  
cell-SELEX not only provides excellent tools for identifying target proteins, it is also a promising 
strategy for the discovery of new disease-related biomarkers. Some examples of target identification 
mediated by cell-SELEX are summarized in Table 1. 
Table 1. Target identification mediated by cell-SELEX. 
Aptamer  Cell Type  Target  Ref. 
GBI-10 (ssDNA)  Glioblastoma cell line U251  tenascin-C  [32] 
aptamer III.1 (ssDNA)  Endothelial cell line YPEN-1  pigpen  [37] 
TD05 (ssDNA)  Burkitt’s lymphoma cell line Ramos  Ig   heavy chain  [36] 
Sgc8 (ssDNA)  T-cell acute lymphoblastic leukemia CCRF-CEM  PTK7  [35] 
A07 (RNA) 
Chinese hamster ovary (CHO) cell line expressing 
recombinant transforming growth factor-βtype III 
receptor 
TGF-βRIII  [38] 
D4 (RNA) 
NGF-different pheochromocytoma cell line PC12 
expressing recombinant MEN2A mutant 
MEN2A mutant 
RET 
[39] 
4. Cell-Specific Aptamers for Targeted Cancer Therapy  
Continued  progress  in  molecular  medicine,  particularly  drugs  targeting  disease-related  cells  or 
proteins,  will  lead  to  cancer  treatment  with  greater  efficacy  and  lower  off-target  toxicity.  Since  
cell-binding aptamers possess excellent targeting properties, they hold a great potential for targeted 
cancer therapy as a therapeutic or delivery agent. 
As mentioned above, aptamers generated by cell-SELEX are able to selectively bind disease-related 
proteins on the cell surface. Therefore, the development of these aptamers as therapeutic agents is 
based on inhibitory activity against their protein targets that are dysregulated in cancer. For example, 
RET  (rearranged  during  transfection)  is  a  receptor  tyrosine  kinase  activated  by  the  glial  cell  
line-derived neurotrophic factor (GDNF) family. Mutations of RET result in constitutive activation 
that causes endocrine neoplasia (MEN) type 2A and 2B syndromes. Certria et al. adopted a cell-SELEX 
strategy  to  select  aptamers  against  the  mutated  form  of  the  human  RET  receptor  [39]. 
Pheochromocytoma-derived  PC12  cells  overexpressing  the  mutant  extracellular  domain  of  RET 
receptor were used for positive selection, while two counter-selection steps were employed against 
parental PC12 cells and PC12 cells overexpressing the wild type extracellular domain of the human 
RET receptor. After 15 rounds of selection, the resulting aptamers not only specifically bound to mutant Int. J. Mol. Sci. 2012, 13                       
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RET, but also inhibited RET activation and effectively blocked the RET-mediated signal transduction 
pathway, which exhibited significant therapeutic potential against the endocrine neoplasia syndrome. 
Recent  cell-SELEX  selection  procedures  have  succeeded  in  producing  anticancer  aptamers  against 
tenascin-C [32] and TGF-β type III receptor [38].  
In  some  cases,  identification  of  the  cell-surface  target  is  not  absolutely  necessary  when  using  
cell-SELEX to generate functional aptamers against cancer. Zueva et al. developed aptamers for the 
specific  recognition  of  highly  metastatic  cells  [40].  Two  malignant  isogenic  hamster  cell  lines,  
HET-SR-1 (HM) and HET-SR (LM), were used for cell-SELEX. Although they are similar in many 
respects, including tumorigenicity and growth properties, the former shows greater metastatic potential 
in vivo than the latter. By using HM for positive selection and LM for counter-selection, aptamers E10 
and E37 were identified that specifically bind to the highly metastatic cell line HM. More importantly, 
the aptamers selected by this process disrupted migration and invasion of tumor cells by decreasing the 
phosphorylation  of  multiple  metastasis-associated  tyrosine  kinases.  In  another  study  using  
cell-SELEX,  Certria’s  group  generated  aptamers  able  to  discriminate  between  two  highly  related 
phenotypes within the same tumor [41]. The malignant human glioma cell line U87MG was used as 
the target for the selection step and a similar, but poorly tumorigenic human glioma cell line, T98G, 
was used for the counter-selection step. They obtained a panel of aptamers capable of binding to target 
cells with high affinity. Interestingly, these aptamers inhibited a specific intracellular signal transduction 
pathway and showed functional activity against tumor cell proliferation.  
Recently, Boltz and co-workers adopted a strategy that combined two DNA aptamers simultaneously 
binding to tumor cell and nature killer cells to mediate specific tumor cell lysis [42]. One of the 
aptamers  was  generated  against  CD16α  expressed  on  NK  cells,  which  plays  a  pivotal  role  in  
antibody-dependent  cellular  cytotoxicity  (ADCC).  The  other  aptamer  was  used  to  bind  to  the 
hepatocyte  growth  factor  receptor  (c-Met),  usually  overexpressed  in  tumor  cells.  c-Met  is  a 
transmembrane receptor tyrosine kinase, which is involved in the proliferation, migration and invasion 
of many cancer types [43]. Two aptamers were connected by an ologonucleotide linker as bi-specific 
aptamers, which can mimic ADCC by recruitment of NK cells via CD16α to c-Met positive tumor cells 
and subsequently specifically killed tumor cells.  
Cell type-specific aptamers that target cancer cell surface receptors have also been exploited as 
carriers for the delivery of a variety of anticancer substances to given cancer cells. Once delivered, 
target-specific  aptamers  selectively increase the  accumulation or retention of therapeutic  agents  in 
cancer cells but spare noncancerous cells in the tissue. Therefore, such aptamers can enhance  the 
therapeutic efficiency and decrease unwanted side effects of conventional chemotherapeutics, such as 
the death of normal cells.  
Prostate specific membrane antigen (PSMA) is a well-known prostate cancer tumor marker which is 
overexpressed on prostate cancer epithelial cells [44]. Studies has shown PSMA can be constitutively 
endocytosed into cells via clathrin-coated pits [45]. Therefore, a strategy to develop PSMA-specific 
aptamers may serve as a poteinal drug delivery vehicles for prostate cancer. In 2002, Lupold et al. 
identified two 2'-fluoro-pyrimidine (2'Fy)-RNA  aptamers that bind to prostate cancer  cells via  the 
extracellular domain of  PSMA [17]. Subsequently, these aptamers have been  employed to deliver 
chemotherapeutic agents [46–48], toxin [49], or siRNA [14,50,51] for targeted prostate cancer therapy.  Int. J. Mol. Sci. 2012, 13                       
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Similarly, aptamer sgc8 specifically binding to acute lymphoblastic leukemia (ALL) T-cells via 
PTK7 on the cell membrane can also be internalized into cells [52]. To develop sgc8 as delivery 
vehicles  for  targeted  therapy  in  leukemia,  we  covalently  conjugated  doxorubicin  (DOX)  to  sgc8c 
which is an optimized and truncated DNA sequence of sgc8 and had identical binding properties as 
sgc8 [53,54]. DOX is an anthracycline-derived drug molecule used to treat many types of cancer, 
including acute lymphoblastic, myelocytic leukemia and malignant lymphomas. However, application 
is limited in clinical practice by high toxicity to non-target cells. The same as free DOX, sgc8c-DOX 
conjugates were cytotoxic to CCRF-CEM cells. More importantly, these conjugates showed excellent 
selective cytotoxicity, increasing toxicity to target CCRF-CEM cells by 6.7-fold compared to the acute 
promyelocytic leukemia cell line NB-4. Recently, the same strategy was also adopted by another group 
to non-covalently link daunorubicin to sgc8, resulting in the specific delivery of daunorubicin to T-cell 
acute lymphoblastic leukemia cells [55]. 
In another example, aptamers generated by cell-SELEX were conjugated to a photosensitizer (PS) 
for the phototherapeutic targeting of tumor cells. Photodynamic therapy (PDT), which has emerged as 
a  promising  treatment  for  cancer,  relies  on  the  interaction  of  excited  photosensitizers  with  ambient 
oxygen  to  produce  reactive  oxygen  species  (ROS)  that  kill  malignant  cells  by  apoptosis  and/or  
necrosis [56]. However, a key challenge in PDT is the targeted delivery of PS to the cancer site. To 
address this problem, Mallikaratchy et al. conjugated the photosensitizer chlorin e6 (c) to the aptamer 
TD05  selected  against  the  Burkitt’s  lymphoma  cell  line  Ramos  [57].  Under  illumination,  the  
TD05-Ce6 complex selectively destroyed the targeted Ramos cells by more than 50% over untargeted 
cells, such as CEM, k562, NB4, and HL60 cell lines.  
5. Cancer Cell Enrichment and Detection Using Aptamers 
Detection of cancer in the early stages can significantly improve survival, but a rare cancer cell in a 
mixture of normal cells is difficult to find in the early stage of pathogenesis, even by a highly trained 
pathologist. Therefore, the development of new technologies for effective enrichment and sensitive 
detection of cancer cells in the early stages will greatly enhance treatment efficacy.  
Based  on  the  unique  properties  of  aptamers  and  gold  nanoparticles,  we  developed  a  sensitive 
colorimetric assay for the detection of cancer cells [58]. An aptamer, generated by cell-SELEX, was 
conjugated to 20-nm gold particles and selectively assembled on the surface of target cells. A significant 
color change resulted because gold nanoparticles possess strong distance-dependent optical properties, 
while non-target cells did not show any change in color. The assay is so sensitive that as few as  
90 cells/sample could be measured.  
By  combining  aptamers  and  DNAzyme,  Zhu  et  al.  developed  an  aptamer-based  colorimetric 
detection assay for the detection of cancer cells [59]. Aptamers were used as the recognition element to 
target cancer cells, while peroxidase-active DNAzyme was adopted to produce the colorimetric signals 
by catalyzing the oxidation of ABTS
2− to the colored ABTS
−. Therefore, by integrating aptamer and 
DNAzyme, it is possible to detect cancer cells based on the color change of a substrate for DNAzyme. 
This method requires no expensive apparatus, modification or labeling of DNA chains; therefore, it 
holds the potential for routine detection of nascent cancer in biopsy specimens. Int. J. Mol. Sci. 2012, 13                       
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To  detect  and  capture  an  extremely  low  concentration  of  cancer  cells  in  bodily  fluids,  an  
aptamer-modified microfluidic device was designed to enrich cancer cells [60]. The aptamer sgc8 was 
linked  to  a  biotin  moiety  at  the  3'  end  for  immobilization  within  a  microfluidic  channel,  and 
fluorescein was added at the 5' end for visualization. These additions did not interfere with the specific 
selectivity of sgc8 for target cells. By using a microfabricated poly(dimethylsiloxane) (PDMS) device, 
we obtained >80% capture efficiency with 97% purity of the target cells.  
To further detect captured cells, a two-nanoparticle assay with aptamers was developed. Aptamers 
linked to magnetic nanoparticles were used for target cell extraction, while aptamers linked to fluorescent 
nanoparticles were simultaneously added for sensitive cell detection [61]. Using 65 nm silica-coated 
magnetic nanoparticles attached to DNA aptamers, target cells were preferentially extracted from a 
sample,  while  only  a  few  control  cells  were  collected.  In  addition,  Ru(bpy)  nanoparticle-aptamer 
conjugates enhanced the fluorescence signal of target cells by more than 100-fold after extraction by 
magnetic nanoparticles compared to Ru(bpy) dye-labeled cells. Therefore, the simultaneous use of 
nanoparticle-labeled aptamers for targeted cell detection and selection allows for the rapid and accurate 
analysis of target cells within a larger non-target population. Furthermore, we have extended this method 
for the collection and detection of multiple cancer cells using high-affinity aptamers for recognition [62].  
6. Conclusion  
Since its discovery in the early 1990s, aptamer technology has made significant strides. In particular, 
recent  advancements  in  SELEX  technology  have  been  extended  from  aptamer  selection  against 
purified protein to selection against living cells, thus enabling the isolation of aptamers that bind to 
cell-specific proteins in situ. Theses aptamers can be applied to many fields of molecular medicine. 
Using cell-based aptamers, different cell types can be distinguished without prior knowledge of the 
target molecules. By integrating other technologies, such as nanotechnology or microfluidic technology, 
aptamers  can  be  used  to  enrich  and  detect  diseased  cells  for  clinical  diagnosis.  Furthermore,  the 
identification  of  aptamer  molecular  targets  constitutes  a  novel  method  of  biomarker  discovery.  
Also, based on the high specificity and easy chemical modification of aptamers, cell-specific aptamers 
can be readily adapted for drug delivery and targeted therapy. Undoubtedly, with the rapid progress  
of  nanotechnology,  microchips,  microfluidic  devices,  RNAi  and  other  advanced  technologies,  
cell-SELEX represents an integrated technology that will revolutionize the way we diagnose, treat and 
prevent disease. 
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